drugset / Trial / NCT05447013
Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients
Phase 1/2
Unknown
182 enrolled
George Papanicolaou Hospital
General Hospital Of Thessaloniki Ippokratio · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Open-label phase I (single-center)/ phase II (multicenter) with randomization 2:1
Timeline
- Start
- 2021-06-02
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Coronavirus-2-specific T cells | Unknown | 1.5e+07 cells | — |
| Subject | Coronavirus-2-specific T cells | Unknown | 2e+07 unknown | — |